These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17073608)

  • 21. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S; Timmis AD
    Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ivabradine: a selective If current inhibitor in the treatment of stable angina.
    Andrikopoulos G; Dasopoulou C; Sakellariou D; Tzeis S; Koulouris S; Kranidis A; Kappos K; Manolis AS
    Recent Pat Cardiovasc Drug Discov; 2006 Nov; 1(3):277-82. PubMed ID: 18221092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. I f inhibition with ivabradine : electrophysiological effects and safety.
    Savelieva I; Camm AJ
    Drug Saf; 2008; 31(2):95-107. PubMed ID: 18217787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heart rate reduction by pharmacological If current inhibition.
    Cargnoni A; Ceconi C; Stavroula G; Ferrari R
    Adv Cardiol; 2006; 43():31-44. PubMed ID: 16936470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes.
    Scheruebel S; Koyani CN; Hallström S; Lang P; Platzer D; Mächler H; Lohner K; Malle E; Zorn-Pauly K; Pelzmann B
    J Mol Cell Cardiol; 2014 Jul; 72(100):64-73. PubMed ID: 24583250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of verapamil, zatebradine, and E-4031 on the pacemaker location and rate in response to sympathetic stimulation in dog hearts.
    Furukawa Y; Miyashita Y; Nakajima K; Hirose M; Kurogouchi F; Chiba S
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1334-42. PubMed ID: 10336524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivabradine: an intelligent drug for the treatment of ischemic heart disease.
    Riccioni G
    Molecules; 2012 Nov; 17(11):13592-604. PubMed ID: 23159921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
    Vilaine JP
    Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blocking effects of acehytisine on pacemaker currents (I(f)) in sinoatrial node cells and human HCN4 channels expressed in Xenopus laevis oocytes.
    Fan X; Chen Y; Xing J; Wu P; Chen H; Yang J; Zhang J; Wang X; Huang C
    J Ethnopharmacol; 2012 Jan; 139(1):42-51. PubMed ID: 22107837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biological effects of ivabradine in cardiovascular disease.
    Speranza L; Franceschelli S; Riccioni G
    Molecules; 2012 Apr; 17(5):4924-35. PubMed ID: 22547315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ivabradine for the Treatment of Cardiovascular Diseases.
    Ide T; Ohtani K; Higo T; Tanaka M; Kawasaki Y; Tsutsui H
    Circ J; 2019 Jan; 83(2):252-260. PubMed ID: 30606942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK; Gray D; Purcell H
    Adv Ther; 2009 Feb; 26(2):127-37. PubMed ID: 19259630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pacemaker channels and sinus node arrhythmia.
    Stieber J; Hofmann F; Ludwig A
    Trends Cardiovasc Med; 2004 Jan; 14(1):23-8. PubMed ID: 14720471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ivabradine: A Unique and Intriguing Medication for Treating Cardiovascular Disease.
    Nawarskas JJ; Bowman BN; Anderson JR
    Cardiol Rev; 2015; 23(4):201-11. PubMed ID: 25839989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug insight: If inhibitors as specific heart-rate-reducing agents.
    Borer JS
    Nat Clin Pract Cardiovasc Med; 2004 Dec; 1(2):103-9. PubMed ID: 16265314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives of I(f) inhibition by ivabradine in cardiology.
    Böhm M; Reil JC
    Drugs; 2007; 67 Suppl 2():43-9. PubMed ID: 17999563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of inappropriate sinus tachycardia with ivabradine.
    Annamaria M; Lupo PP; Foresti S; De Ambroggi G; de Ruvo E; Sciarra L; Cappato R; Calo L
    J Interv Card Electrophysiol; 2016 Jun; 46(1):47-53. PubMed ID: 26467151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.
    Cappato R; Castelvecchio S; Ricci C; Bianco E; Vitali-Serdoz L; Gnecchi-Ruscone T; Pittalis M; De Ambroggi L; Baruscotti M; Gaeta M; Furlanello F; Di Francesco D; Lupo PP
    J Am Coll Cardiol; 2012 Oct; 60(15):1323-9. PubMed ID: 22981555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the management of heart failure: the role of ivabradine.
    Müller-Werdan U; Stöckl G; Werdan K
    Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.